Inside Cover: A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis (Angew. Chem. Int. Ed. 50/2014)

Abstract

… the enzyme responsible for the inactivation of the endocannabinoid 2-arachidonoylglycerol, is a strategy for the treatment of multiple sclerosis. In their Communication on page 13765 ff., M. L. López-Rodríguez and co-workers describe a potent, reversible, and selective inhibitor of MAGL that slows the clinical progression of multiple sclerosis without inducing undesirable CB 1 -mediated side effect.